Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Current Deferred Revenue (2016 - 2026)

Champions Oncology (CSBR) has 15 years of Current Deferred Revenue data on record, last reported at $12.3 million in Q4 2025.

  • For Q4 2025, Current Deferred Revenue rose 20.72% year-over-year to $12.3 million; the TTM value through Oct 2025 reached $12.3 million, up 20.72%, while the annual FY2025 figure was $15.4 million, 27.69% up from the prior year.
  • Current Deferred Revenue reached $12.3 million in Q4 2025 per CSBR's latest filing, down from $14.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $15.4 million in Q2 2025 and bottomed at $5.5 million in Q3 2021.
  • Average Current Deferred Revenue over 5 years is $10.8 million, with a median of $11.1 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: skyrocketed 98.87% in 2022, then dropped 21.38% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $6.1 million in 2021, then surged by 82.65% to $11.2 million in 2022, then rose by 16.07% to $13.0 million in 2023, then fell by 21.38% to $10.2 million in 2024, then grew by 20.72% to $12.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $12.3 million in Q4 2025, $14.4 million in Q3 2025, and $15.4 million in Q2 2025.